AbbVie Ventures is among the backers of a $30m series A round for Disarm Therapeutics, a biotechnology spinout from Washington University in St Louis.
Disarm Therapeutics, a US-based biotechnology developer focused on neurological diseases, raised $30m in a series A round on Tuesday from investors including AbbVie Ventures, the investment arm of pharmaceutical firm AbbVie.
The round was led by Atlas Venture and also included Lightstone Ventures.
Disarm Therapeutics, co-founded, seeded and incubated by Atlas Venture in 2016, is developing treatments for patients suffering from neurological diseases.
The company’s approach aims to inhibit a protein called Sarm1, which has been identified as a driver…
